Guardant Health Inc (Guardant Health) is a precision oncology company that commercializes novel therapeutics for cancer. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection used during cancer treatment for residual disease monitoring and also recurrence monitoring. The company test platform includes GuardantOMNI, GuardantINFINITY and GuardantINFORM. Guardant Health also develops a cloud-based information platform for liquid biopsy-based genomic testing in cancer treatments. The company has operations in the Netherlands, Japan, Singapore, and the US. Guardant Health is headquartered in Pao Alto, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Guardant Health Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Guardant Health Inc Company Overview
- Guardant Health Inc Company Snapshot
- Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview
- Guardant Health Inc - Pipeline Analysis Overview
- Guardant Health Inc - Key Facts
- Guardant Health Inc - Major Products and Services
- Guardant Health Inc Pipeline Products by Development Stage
- Guardant Health Inc Ongoing Clinical Trials by Trial Status
- Guardant Health Inc Pipeline Products Overview
- Anti-RSP03 Antibody Based Blood Test
- Anti-RSP03 Antibody Based Blood Test Product Overview
- cfDNA Diagnostic Assay
- cfDNA Diagnostic Assay Product Overview
- Gene-Based Test - Lung Cancer
- Gene-Based Test - Lung Cancer Product Overview
- Gene-Based Test - Lung Cancer Clinical Trial
- Guardant Reveal Blood Test - Multiple Cancers
- Guardant Reveal Blood Test - Multiple Cancers Product Overview
- Guardant Reveal Blood Test - Multiple Cancers Clinical Trial
- Guardant Shield IVD-CRC Test
- Guardant Shield IVD-CRC Test Product Overview
- Guardant Shield IVD-CRC Test Clinical Trial
- Guardant Shield Lung Test
- Guardant Shield Lung Test Product Overview
- Guardant Shield Lung Test Clinical Trial
- Guardant360 CDx Test - Camizestrant
- Guardant360 CDx Test - Camizestrant Product Overview
- Guardant360 CDx Test - Pembrolizumab
- Guardant360 CDx Test - Pembrolizumab Product Overview
- Guardant360 CDx Test - Taletrectinib
- Guardant360 CDx Test - Taletrectinib Product Overview
- Guardant360 CDx Test - Tepotinib
- Guardant360 CDx Test - Tepotinib Product Overview
- Guardant360 Companion Diagnostic Assay - Glesatinib
- Guardant360 Companion Diagnostic Assay - Glesatinib Product Overview
- Guardant360 Liquid Biopsy Test
- Guardant360 Liquid Biopsy Test Product Overview
- Guardant360 TissueNext - Expanded Version
- Guardant360 TissueNext - Expanded Version Product Overview
- Guardant360 TissueNext PD-L1 Test
- Product Status
- GuardantOMNI Test - Imfinzi
- GuardantOMNI Test - Imfinzi Product Overview
- LUNAR-2 Assay
- LUNAR-2 Assay Product Overview
- LUNAR-2 Assay Clinical Trial
- Next-Generation CGP Tissue Assay
- Next-Generation CGP Tissue Assay Product Overview
- Shield CRC + Lung
- Shield CRC + Lung Product Overview
- Shield Multi-Cancer
- Shield Multi-Cancer Product Overview
- Smart Liquid Biopsy
- Smart Liquid Biopsy Product Overview
- Guardant Health Inc - Key Competitors
- Guardant Health Inc - Key Employees
- Guardant Health Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Guardant Health Inc, Recent Developments
- Jun 04, 2024: Guardant Health Introduces New Guardant360 Tissuenext Test With Nearly 500 Biomarkers To Identify More Treatment Options For Patients With Advanced Cancer
- Jun 03, 2024: Guardant Health and Washington University to Present Study at 2024 Asco Meeting Highlighting Utility of ctDNA to Address Racial Inequities in the Use of Targeted Therapies and Enrollment in Clinical Trials
- May 30, 2024: Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
- May 24, 2024: Guardant wins FDA AdCom backing for colon cancer test
- May 22, 2024: Guardant Health to Participate in Upcoming Investor Conferences
- May 21, 2024: Guardant’s tumour mutation profiling test gains EU IVDR certification
- May 16, 2024: Guardant Health to present real-world data supporting performance of Shield blood test for colorectal cancer screening at 2024 Digestive Disease Week
- May 07, 2024: Guardant Health Surpasses 500 Peer-reviewed Publications Milestone
- Apr 22, 2024: FDA Advisory Panel Review of Guardant Health’s Shield Blood Test to Screen for Colorectal Cancer to Be Held on May 23
- Apr 03, 2024: Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview
- Guardant Health Inc Pipeline Products by Equipment Type
- Guardant Health Inc Pipeline Products by Indication
- Guardant Health Inc Ongoing Clinical Trials by Trial Status
- Guardant Health Inc, Key Facts
- Guardant Health Inc, Major Products and Services
- Guardant Health Inc Number of Pipeline Products by Development Stage
- Guardant Health Inc Pipeline Products Summary by Development Stage
- Guardant Health Inc Ongoing Clinical Trials by Trial Status
- Guardant Health Inc Ongoing Clinical Trials Summary
- Anti-RSP03 Antibody Based Blood Test - Product Status
- Anti-RSP03 Antibody Based Blood Test - Product Description
- cfDNA Diagnostic Assay - Product Status
- cfDNA Diagnostic Assay - Product Description
- Gene-Based Test - Lung Cancer - Product Status
- Gene-Based Test - Lung Cancer - Product Description
- Gene-Based Test - Lung Cancer - Prospective Feasibility Study of Cell Free Circulating Tumor DNA for the Diagnosis and Treatment Monitoring in Early-stage Non-small Cell Lung Cancer
- Guardant Reveal Blood Test - Multiple Cancers - Product Status
- Guardant Reveal Blood Test - Multiple Cancers - Product Description
- Guardant Reveal Blood Test - Multiple Cancers - ORACLE: Observation of ResiduAl Cancer with Liquid Biopsy Evaluation
- Guardant Shield IVD-CRC Test - Product Status
- Guardant Shield IVD-CRC Test - Product Description
- Guardant Shield IVD-CRC Test - Blood-Based Colorectal Cancer (CRC) Screening Implementation Into Clinical Practice in the Outpatient Clinical Settings in the Appalachian Highlands
- Guardant Shield IVD-CRC Test - The Ohio State University Guardant Shield Colorectal Cancer Screening Project
- Guardant Shield IVD-CRC Test - Understanding Patient Preference on Colorectal Cancer Screening Options
- Guardant Shield IVD-CRC Test - Understanding Patient Preference on Colorectal Cancer Screening Options
- Guardant Shield Lung Test - Product Status
- Guardant Shield Lung Test - Product Description
- Guardant Shield Lung Test - Screening for High Frequency Malignant Disease
- Guardant360 CDx Test - Camizestrant - Product Status
- Guardant360 CDx Test - Camizestrant - Product Description
- Guardant360 CDx Test - Pembrolizumab - Product Status
- Guardant360 CDx Test - Pembrolizumab - Product Description
- Guardant360 CDx Test - Taletrectinib - Product Status
- Guardant360 CDx Test - Taletrectinib - Product Description
- Guardant360 CDx Test - Tepotinib - Product Status
- Guardant360 CDx Test - Tepotinib - Product Description
- Guardant360 Companion Diagnostic Assay - Glesatinib - Product Status
- Guardant360 Companion Diagnostic Assay - Glesatinib - Product Description
- Guardant360 Liquid Biopsy Test - Product Status
- Guardant360 Liquid Biopsy Test - Product Description
- Guardant360 TissueNext - Expanded Version - Product Status
- Guardant360 TissueNext - Expanded Version - Product Description
- Product Status
- Guardant360 TissueNext PD-L1 Test - Product Description
- GuardantOMNI Test - Imfinzi - Product Status
- GuardantOMNI Test - Imfinzi - Product Description
- LUNAR-2 Assay - Product Status
- LUNAR-2 Assay - Product Description
- LUNAR-2 Assay - Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
- Next-Generation CGP Tissue Assay - Product Status
- Next-Generation CGP Tissue Assay - Product Description
- Shield CRC + Lung - Product Status
- Shield CRC + Lung - Product Description
- Shield Multi-Cancer - Product Status
- Shield Multi-Cancer - Product Description
- Smart Liquid Biopsy - Product Status
- Smart Liquid Biopsy - Product Description
- Guardant Health Inc, Key Employees
- Guardant Health Inc, Subsidiaries
- Glossary
- Guardant Health Inc Pipeline Products by Equipment Type
- Guardant Health Inc Pipeline Products by Development Stage
- Guardant Health Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Illumina Inc
- ElSohly Laboratories Inc
- Roche Molecular Systems Inc
- NantHealth Inc
- InVitae Corp
- Thermo Fisher Scientific Inc
- Natera Inc
- Qiagen NV
- Novartis Pharmaceuticals Corp
- BioGenex Laboratories Inc
